Register here

  

Current Issue:

The new edition of our newsletter on transactions in the global life sciences industry glances back at the significant deals that took place in 2023 and provides further insights on the industry’s market trends. 

  • 2023 marked a year of progressive M&A recovery for the life sciences industry. Market activity generally bounced back to pre-pandemic levels in respect of deal volume and value despite inhibits due to inflation, macroeconomic, geopolitical and regulatory uncertainties.
  • While facing topline pressure and upcoming patent expiries of prominent Life Science players for the second half of the decade we are expecting a further gradually improving M&A level to accomplish and combine strategic organic growth projects with inorganic growth initiatives.
  • While the pharma and biotech sub-sectors remained focused on precision medicine, particularly in oncology and immunology, assets focused on weight management and cardiovascular health also garnered considerable investor attention.
  • Looking ahead to 2024, the M&A outlook for the life sciences industry appears promising. The market has ample room for consolidation, creating opportunities for strategic acquisitions.